title: Adherence to asthma management guidelines by middle-aged adults with current asthma.
abstract: BACKGROUND
  With the increasing burden of asthma worldwide, much effort has been given to developing and updating management guidelines. Using data from the Tasmanian Longitudinal Health Study (TAHS), the adequacy of asthma management for middle-aged adults with asthma was investigated.
  
  
  METHODS
  Information about spirometry, medication history and current asthma status was collected by the most recent TAHS when participants were in their mid 40s. Only those who reported ever having asthma were eligible for analysis.
  
  
  RESULTS
  Of the 702 participants who reported ever having asthma, 50% had current asthma (n = 351) of whom 71% were categorised as having persistent asthma (n = 98 mild, n = 92 moderate, n = 58 severe). The majority (85.2%) of participants with current asthma had used some form of asthma medication in the past 12 months, but the proportion of the use of minimally adequate preventer medication was low (26%). Post-bronchodilator airflow obstruction increased progressively from mild to severe persistent asthma for those inadequately managed, but not for those on adequate therapy.
  
  
  CONCLUSIONS
  Appropriate use of asthma medication by this middle-aged group of adults with current asthma was inadequate, especially for those with adult-onset moderate or severe persistent disease and without a family history of asthma. These results suggest that proper use of preventer medication could protect against the progressive decline in lung function associated with increasing severity. This has implications not just for poor quality of life, but also for the development of fixed airflow obstruction.
authors.affiliation: Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, Australia. r.kandane@pgrad.unimelb.edu.au
authors.forename: R K
authors.initials: RK
authors.lastname: Kandane-Rathnayake
authors.forename: M C
authors.initials: MC
authors.lastname: Matheson
authors.forename: J A
authors.initials: JA
authors.lastname: Simpson
authors.forename: M L K
authors.initials: ML
authors.lastname: Tang
authors.forename: D P
authors.initials: DP
authors.lastname: Johns
authors.forename: D
authors.initials: D
authors.lastname: Mészáros
authors.forename: R
authors.initials: R
authors.lastname: Wood-Baker
authors.forename: I
authors.initials: I
authors.lastname: Feather
authors.forename: S
authors.initials: S
authors.lastname: Morrison
authors.forename: M A
authors.initials: MA
authors.lastname: Jenkins
authors.forename: G G
authors.initials: GG
authors.lastname: Giles
authors.forename: J
authors.initials: J
authors.lastname: Hopper
authors.forename: M J
authors.initials: MJ
authors.lastname: Abramson
authors.forename: S C
authors.initials: SC
authors.lastname: Dharmage
authors.forename: E H
authors.initials: EH
authors.lastname: Walters
mesh_terms: D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D004363:Drug Utilization / Q000706:statistics & numerical data; D004812:Epidemiologic Methods; D005260:Female; D005541:Forced Expiratory Volume; D005938:Glucocorticoids / Q000008:administration & dosage; D019983:Guideline Adherence / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D010349:Patient Compliance; D017410:Practice Guidelines as Topic; D012646:Self Administration / Q000592:standards; D013648:Tasmania; D014797:Vital Capacity
chemical_list: D018927:Anti-Asthmatic Agents; D005938:Glucocorticoids